WO2000048583A3 - Formulation of 5-ht agonists with nsaids, especially cox-2 inhibitors, for treating migraine - Google Patents

Formulation of 5-ht agonists with nsaids, especially cox-2 inhibitors, for treating migraine Download PDF

Info

Publication number
WO2000048583A3
WO2000048583A3 PCT/US2000/003897 US0003897W WO0048583A3 WO 2000048583 A3 WO2000048583 A3 WO 2000048583A3 US 0003897 W US0003897 W US 0003897W WO 0048583 A3 WO0048583 A3 WO 0048583A3
Authority
WO
WIPO (PCT)
Prior art keywords
inhibitors
nsaids
treating migraine
agonists
formulation
Prior art date
Application number
PCT/US2000/003897
Other languages
French (fr)
Other versions
WO2000048583A2 (en
Inventor
John R Plachetka
Original Assignee
Pozen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pozen Inc filed Critical Pozen Inc
Priority to AU35965/00A priority Critical patent/AU3596500A/en
Publication of WO2000048583A2 publication Critical patent/WO2000048583A2/en
Publication of WO2000048583A3 publication Critical patent/WO2000048583A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

This invention comprises a method of treating migraine in a human comprising co-timely administering of a therapeutically effective amount of a 5-HT agonist coordinated with a therapeutically effective amount of an NSAID, particularly a long-acting NSAID, and particularly of the class of NSAIDs termed cycloocygenase-2 inhibitors (COX-2 inhibitors) such as celecoxib (Celebrex®), rofecoxib (Vioxx®), meloxicam, piroxicam, JTE-522, L-745,337, and NS398, and in some instances, doses below those ordinarily considered as minimum effective doses as to one or both 5-HT agonist and long-acting NSAID. Dosage forms are included herein.
PCT/US2000/003897 1999-02-19 2000-02-16 Formulation of 5-ht agonists with nsaids, especially cox-2 inhibitors, for treating migraine WO2000048583A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU35965/00A AU3596500A (en) 1999-02-19 2000-02-16 Formulation of 5-ht agonists with cox-2 inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25327899A 1999-02-19 1999-02-19
US09/253,278 1999-02-19

Publications (2)

Publication Number Publication Date
WO2000048583A2 WO2000048583A2 (en) 2000-08-24
WO2000048583A3 true WO2000048583A3 (en) 2000-12-07

Family

ID=22959600

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/003897 WO2000048583A2 (en) 1999-02-19 2000-02-16 Formulation of 5-ht agonists with nsaids, especially cox-2 inhibitors, for treating migraine

Country Status (2)

Country Link
AU (1) AU3596500A (en)
WO (1) WO2000048583A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8022095B2 (en) 1996-08-16 2011-09-20 Pozen, Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
CA2348979A1 (en) 1998-11-02 2000-05-11 Merck & Co., Inc. Method of treating migraines and pharmaceutical compositions
SA99191255B1 (en) 1998-11-30 2006-11-25 جي دي سيرل اند كو celecoxib compounds
JP2003503360A (en) * 1999-06-24 2003-01-28 ファルマシア コーポレイション Combination therapy for the treatment of inflammatory diseases
GB9929039D0 (en) * 1999-12-08 2000-02-02 Glaxo Group Ltd Medicaments
GB0002336D0 (en) * 2000-02-01 2000-03-22 Glaxo Group Ltd Medicaments
AU2001285334A1 (en) 2000-08-29 2002-03-13 Peter Van Patten Combination for the treatment of migraine comprising a cyclooxygenase-2 inhibitor and acetylsalicylic acid
EP1524978A2 (en) * 2002-07-19 2005-04-27 Ranbaxy Laboratories, Ltd. Taste masked sumatriptan tablets and processes for their preparation
AU2003303631B2 (en) 2002-12-26 2008-05-29 Nuvo Pharmaceuticals (Ireland) Designated Activity Company Multilayer Dosage Forms Containing NSAIDs and Triptans
PT1534305E (en) 2003-05-07 2007-02-28 Osteologix As Treating cartilage / bone conditions with water-soluble strontium salts
AU2007257652A1 (en) * 2006-06-15 2007-12-21 Novartis Ag Compositions comprising tegaserod alone or in combination with a proton pump inhibitor for treating or preventing gastric injury
CA2722743A1 (en) 2008-04-28 2009-11-05 Zogenix, Inc. Novel formulations for treatment of migraine

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2135884A (en) * 1983-03-09 1984-09-12 Sandoz Ltd Analgesic preparations containing tizanidine and paracetamol
DE19542281A1 (en) * 1995-11-14 1997-05-15 Boehringer Ingelheim Kg Use of Epinastin for the treatment of pain
WO1997038986A1 (en) * 1996-04-12 1997-10-23 G.D. Searle & Co. Substituted benzenesulfonamide derivatives as prodrugs of cox-2 inhibitors
WO1998006392A1 (en) * 1996-08-16 1998-02-19 Pozen, Inc. Formulation of 5-ht agonists
WO1998015275A2 (en) * 1996-10-09 1998-04-16 Algos Pharmaceutical Corporation Method and potentiated composition for treating migraine
WO1998020870A1 (en) * 1996-11-12 1998-05-22 Pozen, Inc. Improved treatment of migraine headache
WO2000025779A1 (en) * 1998-11-02 2000-05-11 Merck & Co., Inc. Method of treating migraines and pharmaceutical compositions

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2135884A (en) * 1983-03-09 1984-09-12 Sandoz Ltd Analgesic preparations containing tizanidine and paracetamol
DE19542281A1 (en) * 1995-11-14 1997-05-15 Boehringer Ingelheim Kg Use of Epinastin for the treatment of pain
WO1997038986A1 (en) * 1996-04-12 1997-10-23 G.D. Searle & Co. Substituted benzenesulfonamide derivatives as prodrugs of cox-2 inhibitors
WO1998006392A1 (en) * 1996-08-16 1998-02-19 Pozen, Inc. Formulation of 5-ht agonists
WO1998015275A2 (en) * 1996-10-09 1998-04-16 Algos Pharmaceutical Corporation Method and potentiated composition for treating migraine
WO1998020870A1 (en) * 1996-11-12 1998-05-22 Pozen, Inc. Improved treatment of migraine headache
WO2000025779A1 (en) * 1998-11-02 2000-05-11 Merck & Co., Inc. Method of treating migraines and pharmaceutical compositions

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HAAG: "Kombianalgetika in der Kopfschmerztherapie", DEUTSCHE APOTHEKER ZEITUNG,DE,DEUTSCHER APOTHEKER ZEITUNG, STUTTGART, vol. 4, no. 138, 22 January 1998 (1998-01-22), pages 43 - 48, XP002079370, ISSN: 0011-9857 *
PAVEL AND BALUCH: "Formulation of Antimigraine Mixtures", STN HCA,XX,XX, vol. 8, no. 121, 22 August 1994 (1994-08-22), XP002078672 *

Also Published As

Publication number Publication date
AU3596500A (en) 2000-09-04
WO2000048583A2 (en) 2000-08-24

Similar Documents

Publication Publication Date Title
WO2000048583A3 (en) Formulation of 5-ht agonists with nsaids, especially cox-2 inhibitors, for treating migraine
AU3984597A (en) Formulation of 5-ht agonists
Lazzaroni et al. Management of NSAID-induced gastrointestinal toxicity: focus on proton pump inhibitors
BR0306872A (en) Compositions and methods of treatment involving peroxisome proliferator-activated receptor gamma agonists and selective cyclooxygenase-2 inhibitors
BRPI0408902A (en) selective cyclooxygenase-2 inhibitor compositions and 5-ht 1b / 1d agonists for the treatment and prevention of migraine
TNSN01053A1 (en) NOVEL COMPOSITIONS COMPRISING A PARTIAL NICOTINE RECEPTOR AGONIST AND AN ANALGESIC AGENT
AU2002302587A1 (en) Acne treatment with lipooxigenase inhibitors
TNSN06439A1 (en) DERIVATIVES OF 2-CARBAMIDE -4-PHENYLTHIAZOLE, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
BRPI0013478B8 (en) medicament comprising pde inhibitor and use of roflumilast
WO2004073632A3 (en) Rapid absorption selective 5-ht agonist formulations
WO2002007721A3 (en) Use of cox-2 inhibitors for preventing immunodeficiency
SE9903997D0 (en) New compounds
EA200500941A1 (en) MEANS FOR TREATING JOINT DISEASES
AU2002215982A1 (en) Topical treatment of mastalgia with arometese inhibitors such as androstendione
AP1862A (en) Pharmaceutical combinations of COX-2 inhibitors and opiates
EP1051995A3 (en) 5HT1 receptor agonists and a cox-2 inhibitor or NSAID for the treatment of migraine
EP1051993A3 (en) 5HT1 receptor agonists and either a COX-2 inhibitor or NSAID for the treatment of migraine
Cryer NSAID gastrointestinal toxicity
AU2203401A (en) Formulations of adenosine a1 agonists
EP1064967A3 (en) 5HT1 receptor agonists, caffeine and either a COX-2 inhibitor or NSAID for the treatment of migraine
EA200500942A1 (en) MEANS FOR TREATING JOINT DISEASES
EP1064948A3 (en) Combination of an 5HT1 receptor antagonist, caffeine and a cyclooxygenase-2 inhibitor for the treatment of migraine
BR9908838A (en) Use of a glucocorticoid, process to treat acute or chronic glomerulonephritis, and pharmaceutical composition to treat glomerulonephritis
WO1999045905A3 (en) Prophylaxis and treatment of migraine headaches with thromboxane synthetase inhibitors and/or receptor antagonists
Epstein Cardiovascular and Renal Effects of COX-2–Specific Inhibitors: Recent Insights and Evolving Clinical Implications

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase